Results 1 to 10 of about 12,405 (251)
Drug-drug interactions with raltegravir
European Journal of Medical Research, 2009 Objective To review all currently published drug-drug interaction studies with the HIV-integrase inhibitor raltegravir. Methods A PubMed search was conducted for all published reports up to August 1, 2009 as well as a review of updated European and US ...
Burger David M
doaj +7 more sources
Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP
Annals of Clinical and Translational Neurology, 2021 Objective Human T‐cell lymphotropic virus 1 (HTLV‐1)‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic, progressive myelopathy. A high proviral load (PVL) is one of the main risk factors for HAM/TSP.
Yoshimi Enose‐Akahata +10 more
doaj +2 more sources
Raltegravir in treatment naïve patients [PDF]
European Journal of Medical Research, 2009 Raltegravir is the first integrase inhibitor approved for the treatment of HIV infection based on the superior efficacy it showed compared to optimized backbone therapy alone in patients harboring multidrug resistant viruses.
Cossarini F, Castagna A, Lazzarin A
doaj +5 more sources
Adverse events of raltegravir and dolutegravir [PDF]
AIDS, 2017 Objective: To compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir. Design: Prospective cohort study.
L. Elzi +8 more
semanticscholar +9 more sources
New therapeutic strategies for raltegravir [PDF]
Journal of Antimicrobial Chemotherapy, 2009 Raltegravir (Isentress) is the first approved HIV integrase inhibitor. Agents in this class target a different viral enzyme compared with agents inhibiting reverse transcriptase and protease. A wide number of patients are currently susceptible to integrase inhibitors, including heavily antiretroviral-experienced patients harbouring drug-resistant ...
Carmen Garrido +2 more
openalex +4 more sources
Raltegravir use in special populations [PDF]
European Journal of Medical Research, 2009 Raltegravir, the first approved integrase inhibitor, has been shown to be virologically effective in Phase II and Phase III clinical trials in both treatment naive and triple class resistant patients. It also has an excellent tolerability profile and lacks significant drug-drug interactions making it an important drug in the treatment of a number of ...
Margaret Johnson
openalex +5 more sources
Brazilian Journal of Veterinary Medicine, 2022 Feline leukemia virus (FeLV) infection was discovered over 50 years ago; however, the serious clinical changes associated with FeLV infection still have great importance in the diagnosis, prevention, and clinical management of symptomatic patients ...
Carla Regina Gomes Rodrigues Santos +5 more
doaj +2 more sources
Clinical Epidemiology, 2010 Frederik N Engsig1, Jan Gerstoft1, Gitte Kronborg2, Carsten S Larsen3, Gitte Pedersen4, Anne M Audelin5, Louise B Jørgensen5, Niels Obel11Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Denmark; 2Department ...
Frederik N Engsig +3 more
doaj +3 more sources
High levels of polymorphisms related to raltegravir resistance among raltegravir‐naïve individuals in Brazil [PDF]
Journal of the International AIDS Society, 2010 7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow ...
Nathalia Mantovani +4 more
openalex +3 more sources
CPT: Pharmacometrics & Systems Pharmacology, 2021 Once‐daily two 600 mg tablets (1200 mg q.d.) raltegravir offers an easier treatment option compared to the twice‐daily regimen of one 400 mg tablet. No pharmacokinetic, efficacy, or safety data of the 1200 mg q.d.
Vera E. Bukkems +4 more
doaj +2 more sources